SEARCH

SEARCH BY CITATION

References

  • 1
    Mokdad AH , Serdula MK , Dietz WH , Bowman BA , Marks JS , Koplan JP . The spread of the obesity epidemic in the United States, 1991–1998. JAMA 1999; 282: 151922.
  • 2
    Flegal KM , Caroll MD , Ogden CL et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002; 288: 172327.
  • 3
    Bjorntorp P . Obesity and diabetes mellitus. In : PorteDJ , SherwinRS , eds . Ellenberg and Rifkin's Diabetes Mellitus, 5th edn . Stanford: Appleton and Lange, 1997; 55364.
  • 4
    Alberti G , Zimmet P , Shaw S , Bloomgarden Z , Kaufman F , Silink M . Type 2 diabetes in the young: the evolving epidemic: The International Diabetes Federation Consensus Workshop. Diabetes Care 2004; 27: 17981811.
  • 5
    Saydah SH , Fradkin J , Cowie CC . Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 33542.
  • 6
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas compared with conventional treatment and risk in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 83753.
  • 7
    Mäkimattila S , Nikkilä K , Yki-Järvinen H . Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 40612.
  • 8
    Yki-Jarvinen H , Kauppila M , Kujansuu E et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. New England Journal of Medicine 1992; 327: 14534.
  • 9
    Sane T , Helve E , Yki-Jarvinen H , Taskinen MR . One-year response to evening insulin therapy in non-insulin-dependent diabetes. Journal of Internal Medicine 1992; 231: 25360.
  • 10
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 85465.
  • 11
    Yki-Jarvinen H , Ryysy L , Kauppila M et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 403743.
  • 12
    Diabetes care and research in Europe: the Saint Vincent declaration. Diabetic Medicine 1990; 7: 360 [no authors listed ].
  • 13
    Gudbjörnsdottir S , Cederholm J , Nilsson PM , Eliasson B , for the Steering Committee of the Swedish National Diabetes Register. The National Diabetes Register in Sweden—an implementation of the St. Vincent declaration for quality improvement in diabetes care. Diabetes Care 2003; 26: 12706.
  • 14
    Nilsson PM , Gudbjörnsdottir S , Eliasson B , Cederholm J , for the Steering Committee of the National Diabetes Register in Sweden. Hypertension in diabetes – trends in clinical control in repeated national surveys from Sweden 1996–99. Journal of Human Hypertension 2003; 17: 3744.
  • 15
    Nilsson PM , Gudbjörnsdottir S , Cederholm J , Eliasson B , for the Steering Committee of the Swedish National Diabetes Register. Smoking patients with diabetes exhibit higher rates of HbA1c and microalbuminuria than non-smokers – data from the Swedish National Diabetes Register. Diabetes Metabolism 2004; 30: 2618.
  • 16
    Cederholm J , Eliasson B , Nilsson PM , Weiss L , Gudbjörnsdottir S , for the Steering Committee of the Swedish National Diabetes Register. Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetic Research and Clinical Practice 2005; 67: 25866.
  • 17
    Eliasson B , Cederholm J , Nilsson PM , Gudbjörnsdottir S . The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996–2003. Diabetic Medicine 2005; 22: 14206.
  • 18
    Jeppson J-O , Sundkvist G , Nordin G . Harmonisation of HbA1c analyses in Sweden (in Swedish). Diabetology News , Swedish Society of Diabetology 2002; 4: 812.
  • 19
    Hoelzel W , Weykamp C , Jeppson J-O et al. IFCC reference system for measurement of Haemoglobin A1c in human blood and the national standardization schemes in the United States, Japan and Sweden: a method-comparison study. Clinical Chemistry 2004; 50: 16674.
  • 20
    Workshop of the Medical Product Agency. Treatment of Type 2 Diabetes. Recommendations for Treatment. Stockholm: Medical Product Agency, 2000.
  • 21
    DeFronzo RA , Goodman AM . Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. New England Journal of Medicine 1995; 333: 5419.
  • 22
    American Diabetes Association. Treatment of hypertension in diabetes (Position Statement). Diabetes Care 1993; 16: 13941401.
  • 23
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 70313.
  • 24
    Chaturvedi N , Bandinelli S , Mangili R , Penno G , Rottiers RE , Fuller JH , on behalf of the EURODIAB Prospective Complications Study Group. Microalbuminuria in type 1 diabetes: rates, risk factors and glycaemic threshold. Kidney International 2001; 60: 21927.
  • 25
    Hall JE . The kidney, hypertension, and obesity. Hypertension 2003; 41: 62533.
  • 26
    de Jong PE , Verhave JC , Pinto-Sietsma SJ , Hillege HL . PREVEND study group, obesity and target organ damage: the kidney. International Journal of Obesity and Relative Metabolism Disorder 2002; 26 (Suppl. 4): S21S24.
  • 27
    Yip J , Mattock MB , Morocutti A , Sethi M , Trevisan R , Viberti G . Insulin resistance in insulin-dependent diabetic patients with microalbumiunuria. Lancet 1003; 342: 8837.
  • 28
    Mykkanen L , Zaccaro DJ , Wagenknecht LE , Robbins DC , Gabriel M , Haffner SM . Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The insulin resistance atherosclerosis study. Diabetes 1998; 47: 793800.
  • 29
    Gotto AM . Triglyceride, the forgotten risk factor. Circulation 1998; 97: 10278.
  • 30
    Gotto AM . Triglyceride as a risk factor for coronary artery disease. American Journal of Cardiology 1998; 82 (9A): 22Q25Q.
  • 31
    Ginsberg HN . New perspectives on atherogenesis role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002; 106: 213742.
  • 32
    American Diabetes Association. Management of dyslipidemia in adults with diabetes (position statement). Diabetes Care 2000; 23 (Suppl. 1): S57S60.
  • 33
    Fazio S , Linton MF . The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Current Atherosclerosis Reports 2004; 2: 14857.
  • 34
    Fontbonne A , Eschwege E , Cambien F , Richard JL , Ducimetiere P , Rosselin GE et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 3004.
  • 35
    Laws A , Reaven G . Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. Journal of Internal Medicine 1992; 1: 2530.
  • 36
    The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993; 329: 97786.
  • 37
    Stratton IM , Adler AI , Holman RR et al, on behalf f the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 40412.
  • 38
    Wroblewski M , Gottsater A , Lindgarde F , Fernlund P , Sundkvist G . Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40–75 years. Diabetes Care 1998; 21: 2505.